Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
January 23, 2025 09:05 ET
|
Outlook Therapeutics, Inc.
Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable,...
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
January 22, 2025 09:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United...
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
January 16, 2025 06:00 ET
|
Outlook Therapeutics, Inc.
ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to...
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
January 08, 2025 09:15 ET
|
Outlook Therapeutics, Inc.
Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J.,...
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
December 27, 2024 08:05 ET
|
Outlook Therapeutics, Inc.
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in...
Outlook Therapeutics® Streamlines Operations
December 13, 2024 16:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
December 04, 2024 08:05 ET
|
Outlook Therapeutics, Inc.
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of...
Outlook Therapeutics® Announces Executive Leadership Transition
December 03, 2024 16:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
November 27, 2024 06:50 ET
|
Outlook Therapeutics, Inc.
Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
November 06, 2024 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...